ERBE-ELEKTROMEDIZIN
6.6.2024 08:12:27 CEST | Business Wire | Press release
Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the largest single investment in the company's history and represents another important part in the global network. The building combines production, product development, logistics and administration. Erbe will now develop and produce medical technology instruments for customers all over the world at its Rangendingen site near Tübingen. With the new building, the company is expanding its capacities and is even better equipped to deal with the consequences of global crises. The building is a pioneering achievement in terms of ecological, social and economic sustainability. Among the guests on May 3 were the Chairman of the Free Democratic Party, Christian Lindner, and the Minister of Economic Affairs of Baden-Württemberg, Dr. Nicole Hoffmeister-Kraut.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603323747/en/
New Erbe production and development building in Rangendingen, Germany (Photo: Business Wire)
On May 3rd, Erbe opened its newest plant in Rangendingen near Tübingen. The new competence center is dedicated to the development and production of medical instruments for our customers around the world. Erbe is expanding its capacities in order to be even more robust in case of supply bottlenecks resulting from international crisis. In this manner, Erbe ensures uninterrupted business operations. This enables us to consistently deliver the highest quality to our customers worldwide.
An important aspect for ensuring continuous economic success is the concept of sustainability. For Erbe, “Made in Germany” means the future of Germany as a business location in harmony with innovative medical technology and a pioneering role for sustainable, responsible entrepreneurship.
“Erbe is a symbol of what makes our country strong,” explained Christian Lindner, Chairman of the Free Democratic Party (FDP) in his speech. He commended the location decision and emphasized the importance of supporting family businesses, stating, “They are the ones who create prosperity.”
“We have set the course for a new standard with our construction project in Rangendingen,” explains Marcus Felstead, Chief Commercial Officer.
“Because tomorrow's customers will place even more value on sustainability than we already do today. We want to meet these demands.”
Both planning and construction of the building had this as a goal. In order to realize ecological, social and economic aspects of the corporate strategy and combine them in an industrial building, Erbe relied on the use of high-quality ecological building materials for the supporting structure and the façade, the use of renewable energy technology and the implementation of numerous measures for an optimal working environment for employees.
A highlight of the building is one of the largest photovoltaic systems in the region. The 2,800 solar panels on the roof with an output of 1 MW produce 610,000 kWh of electricity per year and cover a third of the energy required for operations. This is supplemented by a combined heat and power plant powered by CO2-neutral biogas.
“We implemented the most demanding standards for energy efficiency and achieved KfW Efficiency Level 40 Plus,” explains Christian O. Erbe. “This means, that our building is more than twice as energy efficient compared to conventional structures, making it a leader in the field of sustainable industrial building.”
Up to 500 employees will be working on site. They benefit from a modern, employee-centered working environment. The company's social responsibility also includes a distinctive health concept for employees, including company medical care, health weeks and financial support for sporting activities. There are exercise islands in the building for fitness, a room for yoga, leisure activities and relaxation rooms.
About Erbe Elektromedizin
Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryosurgery
An international network
- 18 international sales and service units
- 4 production sites
- Erbe is active in 110 international markets.
The Erbe workforce
- Over 1,900 employees worldwide
- Some 1,000 of them in Germany
Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tübingen
www.erbe-med.com
info@erbe-med.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603323747/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
90% of IT Leaders See Gaps in AI Threat Readiness, Lenovo Brings Single Point of Accountability to Cyber Resiliency30.6.2026 15:00:00 CEST | Press release
New end-to-end resilience and managed security offerings help organizations reduce security complexity, cut system downtime by up to 50%, and lower remediation costs by up to 40% by bringing devices, security technologies, expert services, and ecosystem partners together under a single operational model As organizations accelerate AI adoption and digital workplace transformation, many are finding that cyber resilience is undermined not by a lack of security tools, but by growing operational complexity and threat sophistication. According to recent research, 90% of IT leaders acknowledge gaps in their ability to defend against AI-driven threats. While security investments continue to grow, many organizations face a different challenge: fragmented accountability. Security operations remain highly distributed and siloed, making it increasingly difficult to coordinate response efforts, maintain end-to-end business continuity, and recover quickly when incidents occur. To help organizations
Tacton Launches Portfolio Performance Intelligence to Help Manufacturers Understand Why Products Win30.6.2026 15:00:00 CEST | Press release
New configuration-aware commercial intelligence capability connects customer requirements, configuration decisions, and business outcomes to optimize win rates, margin and product strategy. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex products, today announced the launch of Portfolio Performance Intelligence, a new analytics capability designed to help manufacturers understand why products win, where margin is created or lost, and which decisions consistently drive successful business outcomes. Manufacturers don't lack data. They lack the context needed to understand why products perform the way they do and why customers choose them. ERP systems show what was sold, CRM platforms track opportunities, and BI tools visualize trends. But when manufacturers try to understand which customer requirements drive demand, which configurations consistently win, or why margins vary across products, regions or segments, the answers are often unclear
SC Therapeutics Initiates REACH2 Trial for Refractory Chronic Cough30.6.2026 15:00:00 CEST | Press release
First-in-class disease-modifying therapeutic aerosol targeting mechano-sensitive ion channels advances into phase 2 clinical evaluation in UK SC Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies that deactivate mechano-sensitive ion channels (MSCs) to treat respiratory and cardiovascular disease, today reports initiation of the REACH2 trial. The study will evaluate the Company's lead product candidate in patients with refractory chronic cough (RCC) – a debilitating condition for which no disease-modifying treatment options currently exist. The trial will be run in three major cough centers across the UK. A Novel, Disease-Modifying Mechanism of Action SC0032, SC Therapeutics' most advanced product candidate, is a proprietary therapeutic aerosol composed entirely of ions endogenous to human airways. Unlike current symptomatic investigational drugs – including P2X3 receptor antagonists and neurokinin-1 (NK1) receptor antagonists that seek to dampen neural hyper
Riskified Study: As AI Drives a Summer Travel Boom, Clunky Security and Scam Fears Threaten Merchant Conversions30.6.2026 14:30:00 CEST | Press release
New 2026 Summer Travel Survey from Riskified finds that digital and AI tools are reshaping how trips are planned, while security and authenticity concerns continue to influence checkout decisions Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released findings from global survey conducted ahead of the 2026 Summer Travel season, exploring consumer travel behavior, booking experiences, and trust in digital and AI-enabled travel tools. The survey, conducted among more than 4,000 consumers across the United States, United Kingdom, China, Japan, Mexico, Brazil, and Colombia, shows strong demand for travel heading into the summer season, alongside continued adoption of digital and AI tools in trip planning. Key findings from the Riskified 2026 Summer Travel Survey include: 81% of consumers use digital platforms for travel planning, with 26% already relying on AI like ChatGPT or Gemini. Leisure remains the dominant purpose of travel at 63%, followed by
Corpay Cross-Border Named the Official Global FX Partner of Fever30.6.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, today announced that its Cross-Border business has entered into an agreement with Fever, a leading global live-entertainment discovery and ticketing platform that specializes in immersive experiences, candlelit concerts, and interactive pop-up events. Under the agreement, Corpay becomes Fever’s exclusive and Official Global Foreign Exchange (FX) Partner. Through this partnership, Fever’s global operations across North America, Mexico, the UK, EMEA, and APAC will be able to leverage Corpay Cross-Border’s innovative solutions to help manage foreign exchange exposure arising from day-to-day business activities. “Fever represents the future of global live entertainment and event ticketing technology, and we are honoured to be named their exclusive and Official FX Partner,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom